Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/101480
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSelva Jové, Laura-
dc.contributor.authorCiruela, Pilar-
dc.contributor.authorBlanchette, Krystle-
dc.contributor.authorAmo Moran, Eva del-
dc.contributor.authorPallarés Giner, Roman-
dc.contributor.authorOrihuela, Carlos J.-
dc.contributor.authorMuñoz-Almagro, Carmen-
dc.date.accessioned2016-08-31T11:01:23Z-
dc.date.available2016-08-31T11:01:23Z-
dc.date.issued2012-07-25-
dc.identifier.issn1932-6203-
dc.identifier.urihttp://hdl.handle.net/2445/101480-
dc.description.abstractStreptococcus pneumoniae is the leading cause of vaccine-preventable deaths globally. The objective of this study was to determine the distribution and clonal type variability of three potential vaccine antigens: Pneumococcal serine-rich repeat protein (PsrP), Pilus-1, and Pneumococcal choline binding protein A (PcpA) among pneumococcal isolates from children with invasive pneumococcal disease and healthy nasopharyngeal carriers. We studied by Real-Time PCR a total of 458 invasive pneumococcal isolates and 89 nasopharyngeal pneumococcal isolates among children (total = 547 strains) collected in Barcelona, Spain, from January 2004 to July 2010. pcpA, psrP and pilus-1 were detected in 92.8%, 51.7% and 14.4% of invasive isolates and in 92.1%, 48.3% and 18% of carrier isolates, respectively. Within individual serotypes the prevalence of psrP and pilus-1 was highly dependent on the clonal type. pcpA was highly prevalent in all strains with the exception of those belonging to serotype 3 (33.3% in serotype 3 isolates vs. 95.1% in other serotypes; P<.001). psrP was significantly more frequent in those serotypes that are less apt to be detected in carriage than in disease; 58.7% vs. 39.1% P<.001. Antibiotic resistance was associated with the presence of pilus-1 and showed a negative correlation with psrP. These results indicate that PcpA, and subsequently Psrp and Pilus-1 together might be good candidates to be used in a next-generation of multivalent pneumococcal protein vaccine.-
dc.format.extent10 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherPublic Library of Science (PLoS)-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0041587-
dc.relation.ispartofPLoS One, 2012, vol. 7, num. 7, p. e41587-
dc.relation.urihttp://dx.doi.org/10.1371/journal.pone.0041587-
dc.rightscc-by (c) Selva Jové, Laura et al., 2012-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationPneumococs-
dc.subject.classificationInfeccions per pneumococs-
dc.subject.classificationVacuna antipneumocòccica-
dc.subject.classificationVacunes-
dc.subject.classificationVacunació dels infants-
dc.subject.classificationResistència als medicaments-
dc.subject.classificationPediatria-
dc.subject.otherStreptococcus pneumonia-
dc.subject.otherPneumococcal Infections-
dc.subject.otherPneumococcal vaccine-
dc.subject.otherVaccines-
dc.subject.otherVaccination of children-
dc.subject.otherDrug resistance-
dc.subject.otherPediatrics-
dc.titlePrevalence and clonal distribution of pcpA, psrP and Pilus-1 among pediatric isolates of Streptococcus pneumoniae-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec640991-
dc.date.updated2016-08-31T11:01:28Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid22848535-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
640991.pdf359.03 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons